Tuesday, June 3, 2025

Dole Advances Public-Private Partnerships to Expand Access to Essential Services for Agricultural Workers

 Ag leader strengthens workplace program that adds social services for thousands of farm workers.


(BUSINESS WIRE) -- Dole (NYSE: DOLE) today announced the signing of new public-private agreements to advance its award-winning Information and Wellbeing Centers (IWCs), a workplace-based initiative pioneered by Dole designed to deliver vital public and private services directly to the workplace, improving quality of life for agricultural workers in Costa Rica’s rural areas.


The announcement was made during the forum “Information and Wellbeing Centers: Public-Private Partnerships that Improve Lives,” hosted by Dole Fresh Fruit. During the event, Dole signed memorandums of understanding with two key national institutions—Caja Costarricense de Seguro Social (CCSS) and Banco Popular—further strengthening its commitment to inclusive development and equitable service access.


Launched in 2020, Dole’s IWC model has redefined how rural workers access healthcare, social security, education, and financial tools. By integrating these essential services directly into the workplace, IWCs eliminate major barriers such as distance, cost, and time. Currently, IWCs directly benefit over 3,300 individuals across four of Dole’s pineapple farms: Santa Fe, El Bosque, La Virgen, and Muelle, thanks to the collaboration of 38 public and private sector partners.


The new agreements with CCSS and Banco Popular—two pillars of Costa Rica’s public infrastructure—signal an expansion of the IWC network:


CCSS (Caja Costarricense de Seguro Social): As Costa Rica’s universal public healthcare and social insurance provider, CCSS plays a central role in delivering medical and social protection across the country.


Banco Popular: A state-owned bank with a social mission focused on financial inclusion and community development, serves working populations and grassroots enterprises across the country.


By formalizing their engagement, these institutions have committed to deepening their participation in the IWC network, advancing broader access to equitable solutions that uphold citizens’ rights and promote long-term well-being.


“This is a concrete example of how public-private partnerships can close gaps and generate real well-being,” said Rudy Amador, Regional Vice President of Social Responsibility, Sustainability, and Communications at Dole Fresh Fruit. “Inter-institutional coordination has been key to making the Information and Wellbeing Centers a powerful driver of inclusion.”


The forum convened national government leaders, business executives and international institutions to reflect on the success and scalability of the IWC model. The Aliarse Foundation, a Costa Rican NGO specializing in cross-sector partnerships, presented a case study during the event, followed by a panel discussion highlighting the social and economic benefits of collaborative development models.


In 2022, the IWC program received the Grand Prize for Social Responsibility in Action from the Costa Rican-American Chamber of Commerce (AMCHAM), recognizing its innovation and measurable impact.


To date, the IWC program has reached 14,947 individuals, with continued expansion planned for the years ahead. The initiative is increasingly recognized as a replicable blueprint for sustainable development.


The event concluded with a collective call to action: when the public sector, private enterprise, and civil society work together with intention, the result is a more just and connected society—one where access to essential services is not a privilege, but a right realized.


About Dole Food Company


Dole Food Company, part of Dole plc, is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250602935679/en/



Permalink

https://www.aetoswire.com/en/news/0206202547126


Contacts

Media Contact:

William Goldfield

818-292-0548

william.goldfield@dole.com

Dubai Retains Global Top Spot for attracting Greenfield FDI Projects in cultural and creative industries in 2024

Dubai, United Arab Emirates - Monday, 02. June 2025

(Dubai Culture) Dubai has maintained its first place as the world’s leading destination for greenfield foreign direct investment (FDI) in the cultural and creative industries (CCI), topping the Financial Times’ fDi Markets ranking for the third consecutive year.

The 2024 report, which assessed 233 cities under the ‘Creative Industries Cluster’ classification, placed Dubai ahead of global hubs such as London and Singapore. During the year, the emirate attracted 971 CCI projects—an 8% increase from 2023—bringing in AED 18.86 billion in capital inflows, up nearly 60% from 2023, and generating 23,517 new jobs, a 9% year-on-year rise.

All major CCI subsectors saw stronger performance, with notable growth in advertising and PR, film and media production, gaming, education, and advanced software design. According to the Dubai FDI Monitor, greenfield, wholly-owned ventures made up 76.5% of all projects, while new forms of investment represented 15.4%, reinvestment 5.6%, and mergers & acquisitions (2.4%).

Data from the Dubai FDI Monitor and the Dubai Framework for Cultural Statistics show that the United States accounted for the largest share of capital inflows in 2024, at 23.2%, followed by India (13.4%), the United Kingdom (9.4%), Switzerland (7.6%), and Saudi Arabia (4.8%). India led in both the number of projects (18.8%) and jobs (18.5%), while the UK, US, Germany, Italy, and France also featured prominently across both metrics.

Investor confidence continues to be driven by Dubai’s pro-business reforms, including Executive Council Resolution 11 of 2025, which enables free zone businesses to operate onshore, expanding commercial flexibility. The city’s Zero Government Bureaucracy programme is also reducing red tape across more than 2,000 federal procedures.

Combined with strong intellectual property protections and advanced digital infrastructure, these initiatives have helped establish a regulatory framework marked by efficiency, transparency, and ease of doing business.

Insights from the ‘Creative Dubai: Navigating Tomorrow’s Creative Landscape’ report  illustrate how this ecosystem is scaling with demand, pinpointing investment opportunity hotspots in design, immersive media and AI-driven production. Dubai continues to offer investors access to top-tier talent, competitive setup costs, and strategic connectivity. The 2024 FDI results underscore the city’s rise as a global hub for innovation and one of the world’s most attractive environments for creative enterprise.

Permalink
https://www.aetoswire.com/en/news/dc02062025

Contacts

Antoine Boghos, +971503310001
antoine@cbpr.me

Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”


 BELLEVUE, Neb. 

Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts.

(BUSINESS WIRE) -- Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals.


“We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.”


As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expertise across its diverse learner and corporate partner network.


Massie continued, “With a network of over 30 manufacturing sites across nine markets, Lenovo’s supply chain is one of our core strengths. By bringing our real-life case studies and insights into the curriculum, we aim to equip students with the skills to succeed in the complex and dynamic working environment. Partnering with Bellevue University, which has a strong track record of working with organizations, allows us to share our knowledge and together build the supply chain experts of the future."


According to a 2024 McKinsey & Company report, a shortage of talent, particularly digital talent, continues to hinder companies’ supply chain transformation efforts. Ninety percent of companies surveyed in the report said they lack sufficient talent to meet digitization goals.


Now, individuals who enroll in the Supply Chain Operations & Project Management Certificate of Completion can gain sought-after skills through two three-credit hour courses – Management of Supply Chain Operations and Advanced Lean Six Sigma Green Belt. The master’s-level courses can be taken concurrently, allowing learners to complete the certificate of completion in under eight months.


“With a deep focus on employee growth planning, we’re uniquely qualified to help adult learners and the employers we partner with upskill or reskill their supply chain workforce,” said Dr. Rich Lombardo, Executive Director of Bellevue University’s Workforce Skills Academy. “Working together, we can ensure that the next generation has the skills and knowledge needed to deal with the complexities that are ever-present in global supply chains.”


Lenovo’s global supply chain leadership provides a singular resource for students and professionals to understand how diversifying manufacturing operations and supply chain resources helps companies thrive during unpredictable periods—a proven, real-world arena for students to apply their education. Lenovo also deploys original AI solutions across its own operations, prioritizes sustainability, and pioneers essential, end-to-end cybersecurity offerings.


Dr. Lombardo added that those who complete the Bellevue-Lenovo program will receive two digital badges, a certificate of completion, and six graduate-level credit hours transferable to a master’s degree.


About Lenovo


Lenovo is a US$69 billion revenue global technology powerhouse, ranked #248 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.


About Bellevue University’s Workforce Skills Academy


Through the Workforce Skills Academy, Bellevue University empowers organizations to transform their workforce with innovative employee growth strategies, consultation and assessment support, custom funding solutions and industry-relevant offerings.


The Workforce Skills Academy is rooted in Bellevue University, a non-profit university founded in 1966 that today has more than 70,000 graduates worldwide. The University is a recognized national leader in preparing students for lifelong success with career-relevant knowledge and skills, while making college affordable. Routinely ranked among the nation’s top military and accessible institutions, the University serves residential students at its main campus in Bellevue, Nebraska, and everywhere online with more than 85 degree programs uniquely designed for working adults. The University is accredited by The Higher Learning Commission (hlcommission.org).


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250602433890/en/



Permalink

https://www.aetoswire.com/en/news/0206202547129


Contacts

Lenovo:

Stuart Gill | Director of Global Media Relations, Campaigns, and Corporate Content, sgill@lenovo.com


Bellevue University:

Cris Hay-Merchant, APR | Vice President, Communications & Community Initiatives, chaymerchant@bellevue.edu

Monday, June 2, 2025

CEOs of The LYCRA Company and Qore® Join Global Fashion Summit Lineup

 


WILMINGTON, Del. - 

LYCRA® Brand and QIRA® are Principal Sponsors of the 2025 Copenhagen Edition


 


(BUSINESS WIRE)--The LYCRA Company, a global leader in developing sustainable fibers and solutions for the apparel industry, announced today that its CEO, Gary Smith, is a speaker at the Global Fashion Summit: Copenhagen Edition 2025. He will be joined on stage by Jon Veldhouse, CEO of Qore®, the maker of QIRA®, a next-generation BDO and a key ingredient in bio-derived LYCRA® fiber, which is launching later this year.


Smith and Veldhouse will discuss the development of this sustainable fiber made from annually renewable field corn during their Fireside Chat: From Farm to Fashion. Their session takes place on Wednesday, June 4, at 3:35 CEST in the DR Concert Hall. The discussion will be moderated by Amy Nguyen, a researcher, writer, and founder of Sustainable & Social.


This is the first time both companies are participating in the Global Fashion Summit, a premier platform focused on sustainability in the fashion industry. The companies have a prominent exhibit space for attendees to learn more about bio-derived LYCRA® fiber made with QIRA®. Here, visitors can be transported to the Qore® site and cornfields in Iowa through a virtual reality experience.


Bio-derived LYCRA® EcoMade fiber will be the world’s first large-scale, commercially available renewable elastane. It delivers equivalent performance to the original LYCRA® fiber and serves as a one-to-one replacement with no re-engineering of fabrics, processes, or garment patterns required. The product contains 70 percent renewable content and can potentially reduce the carbon footprint of LYCRA® fiber by up to 44 percent*. The LYCRA Company holds patents related to this renewable fiber in several regions including Europe.


“We’re proud to join the Global Fashion Summit for the first time and showcase how collaboration can accelerate a more sustainable future for fashion,” said Gary Smith, CEO of The LYCRA Company. “Partnering with Qore® has enabled us to scale innovation that is renewable and ready to meet the demands of global fashion brands striving to meet their sustainability goals.”


The newly constructed Qore® site in Eddyville, Iowa, began operating last month and has started producing QIRA®. The company will host a grand opening celebration in July.


“Starting production at our new state-of-the-art facility marks a major step forward—not just for Qore®, but for the entire industry,” said Jon Veldhouse, CEO of Qore®. “With QIRA® now being made in Iowa from annually renewable field corn, we’re turning sustainable innovation into reality and helping our partners bring next-generation materials to market.”


Learn more about this renewable offering by visiting lycra.com/qira.


*Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc.


About The LYCRA Company


The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at lycra.com.


About Qore® LLC


Formed through a joint venture by Cargill and HELM AG, Qore® helps leading brands replace fossil-based chemistries with bio-derived intermediates. At the heart of the joint venture is the production of QIRA®, the next-generation bio-derived 1,4-butanediol (BDO). Made biologically through the fermentation of plant-based sugars, QIRA® can save up to 86% of greenhouse gas emissions when replacing today’s widely used chemical intermediates made from traditional fossil sources. Bio-derived QIRA® can be used the same way as its fossil counterpart but with significantly better environmental performance. For more information and inquiries, visit https://www.myqira.com/.


About The Global Fashion Summit


Global Fashion Summit is a leading international forum for sustainability in fashion, presented by Global Fashion Agenda (GFA). Convening major decision makers from across the world, the forum was first launched in 2009 and has become a nexus for agenda-setting discussions and presentations on the most critical environmental, social and ethical issues facing our industry and planet, all intended to spark urgent action and accelerate impact in the industry. Learn more at https://bit.ly/3WVUqCd.


LYCRA® is a trademark of The LYCRA Company.


QIRA® is a trademark of Qore®.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250601837469/en/



Permalink

https://www.aetoswire.com/en/news/2062025471155


Contacts

Karie J. Ford

Karie.j.ford@lycra.com

Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania

 NEW YORK - Monday, 02. June 2025 AETOSWire 



Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama


$2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price


Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade


Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025


(BUSINESS WIRE) -- Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news release). The Initial Assessment Technical Report Summary has been filed on Form 6-K with the U.S. Securities and Exchange Commission and made available on EDGAR and the Company’s investor relations website.


Lifezone expects to complete the Kabanga Feasibility Study Technical Report Summary in July 2025, which will focus on the initial development phase of the underground mine and concentrator.


Initial Assessment Technical Report Summary highlights:


This Initial Assessment is preliminary in nature and the economic analysis includes Inferred Mineral Resources that are considered too speculative geologically to have modifying factors applied to them that would enable them to be categorized as Mineral Reserves and there is no certainty that this economic assessment will be realized.


22-year mine plan with a 3.4 million tonnes per annum underground mining operation with total production of 67.9 million tonnes grading 1.93% nickel, 0.26% copper and 0.14% cobalt.


3.4 million tonnes per annum concentrator, producing high-grade nickel, copper, and cobalt concentrate containing a total of 1.15 million tonnes of nickel, 171,000 tonnes of copper and 87,000 tonnes of cobalt.


Hydrometallurgical refinery production design capacity of up to 50,000 tonnes per annum of nickel contained in battery-grade sulfate, up to 7,000 tonnes per annum of London Metal Exchange Grade A 99.99% copper cathode and up to 4,000 tonnes per annum of cobalt in sulfate.


Pre-production capital cost of $991 million, which includes a contingency of 16.1%, with total mine plan revenue from sales estimated at approximately $23.68 billion and after-tax free cash flow of $8.03 billion.


After-tax net present value of $2.37 billion using an 8.0% discount rate and after-tax internal rate of return of 22.9%, based on flat metal prices of $8.49 per pound nickel, $4.30 per pound copper, and $18.31 per pound cobalt.


Low all-in sustaining costs for refined nickel products averaging $2.71 per pound, net of copper and cobalt by-product credits.


Mr. Showalter commented: “The Kabanga Nickel Project represents a rare opportunity to develop a large-scale, high-grade nickel Mineral Resource with robust economics and a clear staged development path to production. The Initial Assessment highlights the project’s potential to deliver positive returns over a long life, supported by a low-cost operating profile, with approximately 80% of the project’s value attributed to the Kabanga mine and concentrator. Our partnership with the Government of Tanzania has been instrumental in advancing the project, and Lifezone remains aligned in our commitment to responsible development and long-term value creation. With the Feasibility Study on track for completion in July, we are very well-positioned to advance the project.”


Mr. Mouton added: “Today marks a significant and historic milestone in the nearly five-decade journey of the Kabanga Nickel Project. For the first time, Lifezone has successfully completed and publicly disclosed a technical-economic Initial Assessment in accordance with U.S. SEC Regulation S-K 1300. This landmark disclosure confirms the reasonable prospects for economic extraction and affirms the project's robust foundation. The Initial Assessment underscores the technical integrity and scalability of Kabanga. Through disciplined engineering and extensive analysis, the Lifezone team has systematically de-risked the development of the underground mine and concentrator. The adopted staged development approach provides a high level of confidence in our ability to deliver a project that is both economically resilient and operationally robust. We remain focused on maintaining this momentum and look forward to the planned completion and release of the Feasibility Study in July 2025.”


TUESDAY: Webcast with Lifezone’s technical leadership team at 10:00 AM ET


The company invites shareholders, investors, and members of the media to join a virtual presentation and discussion of the key highlights of the Initial Assessment.


Date: Tuesday, June 3, 2025.


Time: 10:00 AM Eastern Time.


Location: Virtual (please click the webcast registration link).


The presentation slides will be available on Lifezone’s website, and the webcast will be archived and accessible for replay for a limited time after the event.


Figure 1: Kabanga Nickel Project location in Tanzania.


Figure 2: Overview of the Kabanga site camp.


Kabanga Nickel Project Initial Assessment overview


The Initial Assessment outlines a vertically integrated development plan for the Kabanga Nickel Project, proposing a 3.4 million tonnes per annum underground mining operation processing a total of 67.9 million tonnes of mill feed. The average feed grade is 1.93% nickel, 0.26% copper and 0.14% cobalt, sourced from the Main, MNB, Kima, North and Tembo zones. This supports an estimated 22‑year mine plan.


Nickel, copper and cobalt recoveries are expected to average 87.3%, 95.7% and 89.6%, respectively, through conventional froth flotation. The resulting 17.3% nickel-rich concentrate, containing low levels of deleterious elements, will be exported during the first five years of operation and prior to the commissioning of the Kahama hydrometallurgical refinery. The refinery has a designed production capacity of 50,000 tonnes per annum of nickel as battery-grade nickel sulfate, 7,000 tonnes per annum of London Metal Exchange Grade A 99.99% copper cathode and 4,000 tonnes per annum of cobalt as cobalt sulfate.


The Initial Assessment contemplates pre-production capital expenditures of $991 million, which includes a contingency of 16.1%, capitalized operating expenses of $152 million and $751 million in growth capital – primarily for the refinery. Sustaining capital, including closure costs, is estimated at $1.56 billion. A 2.5-year construction period is planned for the mine and concentrator.


The project economics made use of long-term consensus metal prices. With the metal price assumptions of $8.49 per pound of nickel, $4.30 per pound of copper and $18.31 per pound of cobalt, the Initial Assessment estimates an after-tax net present value (8%) of $2.4 billion and an after-tax internal rate of return of 22.9%.


Table 1: Summary of the Initial Assessment Results.


Kabanga Mine and Concentrator

 


Mine Plan

22 years


Total Mill Feed

67.9 Mt


Nameplate Mill Throughput

3.4 Mtpa


Average Nickel Feed Grade

1.93%


Average Copper Feed Grade

0.26%


Average Cobalt Feed Grade

0.14%


Average Nickel Recovery

87.3%


Average Copper Recovery

95.7%


Average Cobalt Recovery

89.6%


Total Concentrate Produced

7,263 kt wet


Average Nickel Concentrate Grade

17.3%


Moisture Content of Concentrate

9.0%


Total Nickel Production (in concentrate)

1,146 kt


Total Copper Production (in concentrate)

171 kt


Total Cobalt Production (in concentrate)

87 kt


Kahama Refinery

 


Average Nickel Refinery Recovery

97.2%


Average Copper Refinery Recovery

93.0%


Average Cobalt Refinery Recovery

97.7%


Total Nickel Sulfate Produced

3,419 kt


Total Copper Cathode Produced

110 kt


Total Cobalt Sulfate Produced

272 kt


Operating Costs

 


Mining

$54.24/t processed


Concentrator and Infrastructure

$12.37/t processed


Kahama Refinery

$18.57/t processed


Owner’s Cost, Administration and Overhead Costs

$4.88/t processed


Total Operating Costs

$90.06/t processed


All-In Sustaining Costs

 


Mining

$1.60/lb payable Ni


Concentrator

$0.36/lb payable Ni


G&A

$0.12/lb payable Ni


Concentrate Transport and Insurance

$0.22/lb payable Ni


Refinery - Kahama, Transport and Insurance

$0.81/lb payable Ni


Total Cash Cost (before by-product credits)

$3.11/lb payable Ni


Royalties

$0.72/lb payable Ni


Sustaining Capital Expenditures

$0.64/lb payable Ni


All-In Sustaining Costs (before by-product credits)

$4.47/lb payable Ni


Copper By-Product Credit

-$0.56/lb payable Ni


Cobalt By-Product Credit

-$1.20/lb payable Ni


Total All-In Sustaining Costs

$2.71/lb payable Ni


Capital Expenditures

 


Pre-Production Capex

$991M


Capitalized Opex

$152M


Growth Capex

$751M


Sustaining Capex (incl. Closure)

$1,557M


Valuation Metrics

 


Flat-Lined Nickel Price

$8.49/lb


Flat-Lined Copper Price

$4.30/lb


Flat-Lined Cobalt Price

$18.31/lb


Discount Rate

8.0%


After-Tax Net Present Value

$2,374


After-Tax Internal Rate of Return

22.9%


Payback Period from Final Investment Decision (incl. 2.5-year construction period)

9.8 years


Capital Efficiency (NPV/Pre-Production Capex incl. Capitalized Opex)

2.1


Capital Efficiency (NPV/Pre-Production + Growth Capex)

1.3


Table 2: Kabanga Mineral Resource Estimates3 as at December 4, 2024.


Mineral Resource Classification Lifezone

Tonnage3 Grades (%) Recovery (%)

(million tonnes) NiEq24 Nickel Copper Cobalt Nickel Copper Cobalt

MINERAL RESOURCE ALL ZONES – Massive Sulfide plus Ultramafic  

Measured

15.9


2.48


1.95


0.26


0.16


82.7


92.0


85.4


Indicated

31.0


2.69


2.16


0.30


0.16


82.9


92.6


85.3


Measured + Indicated

46.8


2.62


2.09


0.29


0.16


82.8


92.4


85.3


Inferred

11.3


2.59


2.08


0.28


0.15


83.7


93.7


86.5


1.


 

This table reports the Mineral Resources for the combined massive sulfide and ultramafic mineralization types.


2.


 

There are no Mineral Reserves to report as at date of this Initial Assessment Technical Report Summary.


3.


 

Mineral Resources are reported showing only the Lifezone-attributable tonnage portion, which is 69.713% of the total.


4.


 

Cut-off applies to NiEq24, which is derived using a nickel price of USD9.50/lb, copper price of USD4.50/lb, and cobalt price of USD23.00/lb with allowances for recoveries, payability, deductions, transport, and royalties.


5.


 

NiEq24 formulae are: MSSX NiEq24 = Ni + (Cu x 0.454) + (Co x 2.497); UMAF NiEq24 = Ni + (Cu x 0.547) + (Co x 2.480).


6.


 

The point of reference for Mineral Resources is the point of feed into a concentrator.


7.


 

All Mineral Resources in the 2024 Mineral Resource Update were assessed for reasonable prospects for economic extraction by reporting only material above cut-off grades of: MSSX NiEq24>0.73% and UMAF NiEq24>0.77%.


8.


 

Totals may vary due to rounding.


The Initial Assessment is based on the December 2024 Mineral Resource Update, which includes 46.8 million tonnes of attributable Measured and Indicated Mineral Resources grading 2.09% nickel, 0.29% copper and 0.16% cobalt, and 11.3 million tonnes of attributable Inferred Mineral Resources grading 2.08% nickel, 0.28% copper and 0.15% cobalt. The Kabanga Nickel Project is 69.713% owned by Lifezone, and all Mineral Resources are shown on an attributable to Lifezone basis.


For a discussion of Lifezone’s Framework Agreement with the Government of Tanzania relating to the Kabanga Nickel Project, including equitable sharing of the economic benefits, see Item 10 C of the Lifezone‘s Annual Report on Form 20-F for the year ended December 31, 2024 on the Company’s website or sec.gov.


The Initial Assessment is preliminary in nature and includes economic analyses that incorporate Inferred Mineral Resources, which are considered too speculative geologically to be classified as Mineral Reserves. There is no certainty that the results of the Initial Assessment will be realized.


For a scenario excluding Inferred Mineral Resources, the Initial Assessment estimates an after-tax net present value (8.0%) of $2.02 billion and an after-tax internal rate of return of 23.0%, reflecting a slightly higher average feed grade but lower total tonnage.


The capital cost, operating cost and sustaining capital cost estimates were prepared for the project as part of the Initial Assessment. The estimates are classified as being at an Association for the Advancement of Cost Engineering Class 5 level, with an accuracy range of ±50%, consistent with early-stage evaluation standards under Regulation S-K 1300. These estimates support the economic analysis undertaken for the Initial Assessment and demonstrate the reasonable prospects for economic extraction of the reported Mineral Resources.


Figure 3: Production schedule with Measured, Indicated and Inferred Mineral Resources.


The Initial Assessment also outlines a sustainable tailings management strategy in line with Global Industry Standard on Tailings Management and Australian National Committee on Large Dams best practices. Approximately 52% of non-pyrrhotite tailings will be returned underground as paste aggregate fill, blended at 55% tailings and 45% waste rock with cement. The remaining pyrrhotite tailings will be stored in a fully lined downstream constructed tailings storage facility with a leakage collection system and subaqueous deposition to mitigate oxidation risks. The tailing storage facility is designed to accommodate up to 50 million tonnes and withstand a 1:10,000-year storm event. Closure plans include a water-shedding landform and multi-layer cover system. The design has been reviewed by an Independent Tailings Review Board, Government of Tanzania regulators and other industry experts.


Robust Initial Assessment economics for a globally significant source of nickel, copper and cobalt


A preliminary mine design, accessing Measured and Indicated Mineral Resources as well as Inferred Mineral Resources, outlines a 22-year mine plan for the project, with total underground production of 67.9 million tonnes grading 1.93% nickel, 0.26% copper and 0.14% cobalt. During the first five years of operation, the project will export a high-grade nickel-copper-cobalt concentrate while the hydrometallurgical refinery at Kahama is being developed. Once operational, the refinery will promote in-country beneficiation by producing battery-grade nickel and cobalt sulfate products and London Metal Exchange-grade copper cathode, in line with the Government of Tanzania’s expectations.


Total operating costs are projected to average approximately $90 per tonne processed, inclusive of mining, processing, refining, general and administrative, and logistics. AISC for refined nickel is estimated to average $2.71 per pound, net of copper and cobalt by-product credits.


Pre-production capital expenditures are estimated at $991 million, with a 16.1% contingency, covering underground mine development, concentrator construction, tailings storage facility, and supporting infrastructure. Capitalized operating costs are expected to total $152 million. Growth capital of $751 million is primarily allocated to the construction of the Kahama refinery. Sustaining capital over the mine plan is projected at $1.56 billion, including closure costs.


Figure 4: Estimated project cash flows.


The project economics made use of long-term consensus metal prices. Metal price assumptions, of $8.49 per pound of nickel, $4.30 per pound of copper, and $18.31 per pound of cobalt, were used in the Initial Assessment to estimate total project revenue of $23.68 billion. The project is expected to generate $8.03 billion of after-tax undiscounted free cash flow, with an after-tax net present value (8.0%) of $2.37 billion and an after-tax internal rate of return of 22.9%.


The Initial Assessment also demonstrates strong downside resilience to nickel price fluctuation. Applying a sensitivity analysis at $7.00 per pound nickel price, the project maintains an after-tax net present value of $1.48 billion and an after-tax internal rate of return of 17.9%. This economic robustness is underpinned by the project’s high-grade Mineral Resource, valuable copper and cobalt by-products, low all-in sustaining costs and high capital efficiency.


Figure 5: Sensitivity analysis of after-tax net present value (8%).


Phased underground mine development enhances capital efficiency and operational readiness


The Initial Assessment outlines a phased underground mine development strategy at Kabanga, designed to optimize capital efficiency and support an achievable production ramp-up. The mine will be accessed via declines from two boxcuts at the North and Tembo zones. Kima zone will share access from the North decline, while the Main and MNB zones are accessed via the North Mine. The underground operation will ramp up to a steady state rate of 3.4 million tonnes per annum which will feed the concentrator.


Figure 6: Proposed mine design.


Mining will be conducted using longhole stoping with paste backfill, with level spacing of 25 meters and stope strike lengths ranging from 20 to 30 meters. The mining sequence prioritizes the high-grade portions of the North zone. The North and Kima zones are expected to supply approximately 65% of the total mineralized material, followed by Tembo (25%) and Main and MNB (10%). The mine design incorporates detailed geotechnical modeling, ventilation planning, and a robust backfill system to ensure safe and efficient operations.


The development schedule includes a 2.5-year construction period followed by a 2.5-year ramp-up phase, during which critical infrastructure such as ventilation raises, pumping systems, and underground services will be established. The first five years of mining will be executed by a contract mining firm selected through a competitive tender process, ensuring experienced execution and cost control during the early stages of operation.


Figure 7: Proposed mine design sequence (in years).


Further Exploration Targets offer significant upside potential


The Initial Assessment Technical Report Summary also discloses an overall Exploration Target of 17.5 to 23.5 million tonnes grading 1.9% to 2.1% nickel equivalent from four high-priority Exploration Targets within the Special Mining Licence, offering the potential to extend the mine plan and potentially enhance project value. These Exploration Targets, located at Safari Link, Safari Extension, Rubona Hill, and Block 1 South, are based on geophysical anomalies, historical drilling and geological continuity with known mineralized zones.


The ranges of potential tonnage and grade of the Exploration Targets are conceptual in nature. There has been insufficient exploration to estimate a Mineral Resource for these target areas. It is uncertain if further exploration will result in the estimation of a Mineral Resource.


Table 3: Exploration Target summary.


Exploration Target Mineralization

Type Estimated

Tonnage

(Mt) Estimated

Grade

(NiEq24%)

Safari Link Ultramafic 1.5 - 2.0 1.2 - 1.4%

Massive Sulfide 3.0 - 3.5 2.5 - 2.8%

Total 4.5 - 5.5 2.1 - 2.3%

Safari Extension Massive Sulfide plus Ultramafic 3.0 - 4.0 1.8 - 2.0%

Rubona Hill Ultramafic 8.0 - 10.0 1.8 - 2.0%

Block 1 South Ultramafic 2.0 - 4.0 1.8 - 2.0%

Total All

-


17.5 - 23.5 1.9 - 2.1%

Lifezone has allocated a portion of the growth capital expenditures to support drilling and geophysical surveys across these targets, with the aim of delineating additional resources and supporting potential future expansions.


Figure 8: Location of Safari Link and Safari Extension exploration targets with airborne Versatile Time-Domain Electromagnetic background and interpreted major faults.


Efficient sulfide concentrate production with high recoveries at the Kabanga concentrator


The Initial Assessment outlines a conventional concentrator facility at Kabanga, designed to process 3.4 million tonnes per annum and produce a high-grade nickel-copper-cobalt concentrate. The flowsheet, comprising crushing, wet grinding, flotation and dewatering, has been developed through extensive metallurgical testwork to suit the deposit’s mineralogy, including massive sulfide, semi-massive sulfide and ultramafic-hosted zones.


The concentrator is expected to achieve average metallurgical recoveries of 87.3% for nickel, 95.7% for copper and 89.7% for cobalt. The resulting concentrate, grading approximately 17.3% nickel, 2.6% copper and 1.3% cobalt, is low in deleterious elements and well-suited for downstream refining.


The high-grade, low-impurity nature of Kabanga’s concentrate has received strong interest from potential offtake partners for both nickel concentrate and refined battery-grade products. Indicative, non-binding terms have been obtained for 100% of the concentrate produced during the first five years of operations, prior to the commissioning of the Kahama refinery. Lifezone is also exploring strategic partnerships to support long-term marketing of nickel and cobalt sulfates into the electric vehicle markets.


High recoveries of battery-grade metals enabled by hydrometallurgical refining at Kahama


The Initial Assessment includes the Kahama refinery as a cornerstone of Lifezone’s vertically integrated strategy, employing a hydrometallurgical process to produce battery-grade nickel and cobalt sulfate products and London Metal Exchange Grade A 99.99% copper cathode. In the Initial Assessment, a refinery demonstration plant will be constructed and operated at the Kahama site once nickel concentrate is available from Kabanga, but prior to the full-scale refinery construction and operation. This will be undertaken to optimize and finalize the hydrometallurgical flowsheet and further de-risk the refinery.


Designed to process concentrate from the Kabanga mine, the refinery is expected to achieve average metal recoveries from concentrate of 97.2% for nickel, 93.0% for copper and 97.7% for cobalt. The flowsheet incorporates pressure oxidation, neutralization, solvent extraction, electrowinning and crystallization, enabling the designed production of approximately 50,000 tonnes per annum of nickel as nickel sulfate, 7,000 tonnes of copper cathode and 4,000 tonnes of cobalt as cobalt sulfate. All products are expected to meet stringent purity standards for use in electric vehicle batteries.


Figure 9: Allocated refinery site at Kahama.


Strategically located within Tanzania’s Buzwagi Special Economic Zone, the Kahama refinery benefits from existing bulk infrastructure and supports the country’s industrialization goals. By refining metals in-country with hydrometallurgy, the project is expected to have a reduced carbon dioxide emissions footprint compared to traditional smelting and overseas processing and enhances supply chain transparency.


Integrated logistics network strengthened by national infrastructure upgrades


The Kabanga Nickel Project is supported by a logistics network that connects the Kabanga mine site to the Kahama refinery and international export markets. Nickel-copper-cobalt concentrate will be transported approximately 348 kilometers by road from Kabanga to the Isaka Dry Port (rail terminal), using third-party haulage and sealed Flexible Bulk Containers. From Isaka, the concentrate will be transferred onto the Standard Gauge Railway, which is expected to be operational in 2026, for shipment to the Kwala Dry Port and then via dedicated “Port Link” to the Port of Dar es Salaam, into bulk sea freight vessels.


Once the Kahama Refinery begins operations, concentrate will be trucked approximately 320 kilometers by road from Kabanga to the refinery. The refined products, nickel sulfate, copper cathode and cobalt sulfate, will then be transported approximately 30 kilometers by road to Isaka Dry Port, loaded onto the Standard Gauge Railway, and transported via the same route to the Port of Dar es Salaam for export.


Recent national infrastructure investments, including the Standard Gauge Railway, expanded port capacity at Dar es Salaam and the Julius Nyerere Hydropower Project, are expected to enhance the efficiency, reliability and sustainability of the project’s logistics operations.


Figure 10: Standard Gauge Railway locomotives in operation.


Strong ESG credentials aligned with global best practices


The Kabanga Nickel Project is committed to aligning with both Tanzanian regulatory requirements and internationally recognized ESG standards. The project operates within the legal framework of Tanzania, complying with national laws related to environmental protection, social impact management, land access, resettlement, and permitting.


The Project also seeks alignment with leading international ESG frameworks. These include the International Finance Corporation Performance Standards, Equator Principles, Global Industry Standard on Tailings Management and guidelines issued by the and Australian National Committee on Large Dams and International Council on Mining and Metals, ensuring the adoption of sustainable and responsible mining practices.


Comprehensive Environmental and Social Impact Assessments have been completed and approved by Tanzania’s National Environment Management Council for the mine, refinery and resettlement sites.


A Resettlement Action Plan, aligned with International Finance Corporation Performance Standard 5, ensures fair and sustainable relocation for affected communities, with 96% of the required cash compensation already paid, allowing access to the Project footprint as required.


Catalyzing economic growth and industrial development in Tanzania


The Kabanga Nickel Project is poised to deliver long-term economic benefits to Tanzania through job creation, infrastructure development, and domestic value addition. By integrating mining and refining operations within the country, the project directly supports the government’s vision for local beneficiation and industrialization.


The Framework Agreement with the Government of Tanzania for development of the Kabanga Nickel Project ensures that the economic value generated by the project is equitably shared with the Government of Tanzania, contributing to national development goals and community upliftment. Construction and operations are expected to generate thousands of direct and indirect jobs, stimulate local supply chains, and build technical capacity in mining and metallurgy.


The Kahama Refinery, located in the Buzwagi Special Economic Zone, will position Tanzania as a regional hub for battery metals processing. This strategic investment is expected to attract further capital and reinforce Tanzania’s role in the global clean energy transition.


Next steps and strategic recommendations


As one of the world’s largest undeveloped high-grade nickel sulfide deposits, the Kabanga Nickel Project is uniquely positioned to support the global energy transition. With its integrated mine-to-refinery model and strong partnership with the Government of Tanzania, Kabanga offers a scalable, long-life supply of nickel, copper and cobalt.


With the Initial Assessment complete, the project will advance to the completion of a Feasibility Study for the underground mine and concentrator, supported by a Mineral Reserve Statement. The target for completion of the Feasibility Study is July 2025.


To support the Kabanga project development, Lifezone is pursuing a diversified funding strategy that includes a mix of equity, strategic partnerships, and project-level debt. Discussions are ongoing with development finance institutions, commercial lenders, and potential strategic investors. The project’s attractive economics, low operating costs and alignment with global critical minerals priorities position Kabanga as a compelling candidate for sustainable financing. Lifezone expects to finalize the funding package following completion of the Feasibility Study.


Qualified Persons


The “Initial Assessment – Technical Report Summary Kabanga Nickel Project” is dated June 2, 2025 and was prepared by DRA Projects (Pty) Ltd. and Sharron Sylvester in accordance with the United States Securities and Exchange Commission’s (Modernized Property Disclosure Requirements under Subpart 229.1300 of Regulation S-K and Item 601(b)(96).


Sharron Sylvester, BSc (Geol), RPGeo AIG (10125), is employed as Technical Director – Geology, OreWin Pty Ltd, and was responsible for the preparation of the sections relating to geology and Mineral Resources as the QP (individual), excluding cut-off grade and reasonable prospects assessments.


DRA is a third-party firm comprising mining experts in their respective fields in accordance with 17 CFR § 229.1302(b)(1). Lifezone has determined that the appointed consultants meet the qualifications specified under the definition of QP in 17 CFR § 229.1300.


The Initial Assessment Technical Report Summary includes relevant information regarding the assumptions, parameters and methods of the Initial Assessment on the Kabanga Nickel Project, along with the previously-reported Mineral Resource estimates as well as information regarding data verification, exploration procedures and other matters relevant to the scientific and technical disclosure contained in this news release.


If you would like to sign up for Lifezone Metals news alerts, please register here.


Social Media


LinkedIn | X | YouTube


About Lifezone Metals


Lifezone Metals (NYSE: LZM) is committed to delivering cleaner and more responsible metals production and recycling. Through the application of our Hydromet Technology, we offer the potential for lower energy consumption, lower emissions and lower cost metals production compared to traditional smelting.


Our Kabanga Nickel Project in Tanzania is believed to be one of the world's largest and highest-grade undeveloped nickel sulfide deposits. By pairing it with our Hydromet Technology, we are working to unlock a new source of nickel, copper and cobalt for the global battery metals markets and to empower Tanzania to achieve full in-country value creation.


Through our US-based recycling partnership, we are working to demonstrate that our Hydromet Technology can process and recover platinum, palladium and rhodium from responsibly sourced spent automotive catalytic converters. Our process is expected to be cleaner and more efficient than conventional smelting and refining methods, enabling the circular economy for precious metals.


https://lifezonemetals.com


Forward-Looking Statements


Certain statements made herein are not historical facts but may be considered “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995 regarding, amongst other things, the plans, strategies, intentions and prospects, both business and financial, of Lifezone Metals Limited and its subsidiaries.


Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements may be accompanied by words such as “believes,” “estimates,” “expects,” “predicts,” “projects,” “forecasts,” “may,” “might,” “will,” “could,” “should,” “would,” “seeks,” “plans,” “scheduled,” “possible,” “continue,” “potential,” “anticipates” or “intends” “or the negatives of these terms or variations of them or similar terminology or expressions that predict or indicate future events or trends or that are not statements of historical matters; provided that the absence of these does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding future events, the estimated or anticipated future results of Lifezone Metals, future opportunities for Lifezone Metals, including the efficacy of Lifezone Metals’ hydrometallurgical technology (Hydromet Technology) and the development of, and processing of mineral resources at, the Kabanga Nickel Project, and other statements that are not historical facts.


These statements are based on the current expectations of Lifezone Metals’ management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Lifezone Metals and its subsidiaries. These statements are subject to a number of risks and uncertainties regarding Lifezone Metals’ business, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political and business conditions, including but not limited to economic and operational disruptions; global inflation and cost increases for materials and services; reliability of sampling; success of any pilot work; capital and operating costs varying significantly from estimates; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; changes in government regulations, legislation and rates of taxation; inflation; changes in exchange rates and the availability of foreign exchange; fluctuations in commodity prices; delays in the development of projects and other factors; the outcome of any legal proceedings that may be instituted against Lifezone Metals; our ability to obtain additional capital, including use of the debt market, future capital requirements and sources and uses of cash; the risks related to the rollout of Lifezone Metals’ business, the efficacy of the Hydromet Technology, and the timing of expected business milestones; the acquisition of, maintenance of and protection of intellectual property; Lifezone’s ability to achieve projections and anticipate uncertainties (including economic or geopolitical uncertainties) relating to our business, operations and financial performance, including: expectations with respect to financial and business performance, future operating results, financial projections and business metrics and any underlying assumptions; expectations regarding product and technology development and pipeline and market size; expectations regarding product and technology development and pipeline; future acquisitions, partnerships, or other relationships with third parties; maintaining key strategic relationships with partners and customers; the timing and significance of contractual relationships; the effects of competition on Lifezone Metals’ business; the ability of Lifezone Metals to execute its growth strategy, the development and processing of the mineral resources at the Kabanga Nickel Project; obtaining additional capital, including use the debt market, future capital requirements, and sources and uses of cash; manage growth profitably and retain its key employees; the ability of Lifezone Metals to reach and maintain profitability; enhancing future operating and financial results; complying with laws and regulations applicable to Lifezone Metals’ business; Lifezone Metals’ ability to continue to comply with applicable listing standards of the NYSE; the ability of Lifezone Metals to maintain the listing of its securities on a U.S. national securities exchange; our ability to comply with applicable laws and regulations; stay abreast of accounting standards, or modified or new laws and regulations applying to our business, including privacy regulation; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange Commission (SEC) meeting future liquidity requirements and complying with restrictive covenants related to long-term indebtedness; and dealing effectively with litigation, complaints, and/or adverse publicity.


The foregoing list of risk factors is not exhaustive. There may be additional risks that Lifezone Metals presently does not know or that Lifezone Metals currently believes are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide Lifezone Metals’ expectations, plans or forecasts of future events and views as of the date of this communication. Lifezone Metals anticipates that subsequent events and developments will cause Lifezone Metals’ assessments to change.


These forward-looking statements should not be relied upon as representing Lifezone Metals’ assessments as of any date subsequent to the date of this communication. You should not place undue reliance on forward-looking statements in this communication, which are based upon information available to us as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. In all cases where historical performance is presented, please note that past performance is not a credible indicator of future results.


Except as otherwise required by applicable law, we disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data, or methods, future events, or other changes after the date of this communication.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250602829321/en/



Permalink

https://www.aetoswire.com/en/news/0206202547128


Contacts

Investor Relations – North America

Evan Young

SVP: Investor Relations & Capital Markets

evan.young@lifezonemetals.com


Investor Relations – Europe

Ingo Hofmaier

Chief Financial Officer

ingo.hofmaier@lifezonemetals.com

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

 SAN CARLOS, Calif. - Monday, 02. June 2025



Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitor


Data underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation


(BUSINESS WIRE) -- BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure.


“Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne. “These early results highlight the strong potential of our B7-H4-targeting ADC and CDK2 inhibitor to address critical gaps in breast cancer treatment. Alongside our advancing CDK4 inhibitor, they represent just the beginning of a pipeline built on targeted, biology-driven innovation. As we debut our new identity as BeOne, this milestone reflects the momentum behind our science and our commitment to delivering impactful therapies to cancer patients worldwide.”


BeOne is advancing a robust pipeline of differentiated investigational medicines for breast cancer that may both effectively combat the disease and potentially improve quality of life for patients receiving treatment.


BG-C9074, a B7-H4-targeting ADC (Abstract #3033)


BeOne presented initial results of the ongoing first-in-human, Phase 1a dose escalation study of BG-C9074 monotherapy in 78 patients with advanced solid tumors, of which more than a quarter were breast cancer patients. BG-C9074, an investigational topoisomerase I inhibitor ADC that targets the B7-H4 protein, which is broadly expressed in breast and gynecologic cancers, is designed with an innovative drug linker to deliver a potent cancer-killing drug directly to the cancer cells.


With limited follow-up among the 56 efficacy-evaluable patients, preliminary clinical responses were observed at multiple dose levels across various tumor types without selection for B7-H4 expression in these heavily pretreated patients. Confirmed overall response rate (ORR) was 16.1% (9/56; 95% CI: 7.6%–28.3%), with 9 confirmed partial responses; unconfirmed ORR was 25.0% (14/56; 14.4%-38.4%) (n=14 partial responses). Confirmed disease control rate (DCR) was 73.2% (59.7%-84.2%) and confirmed clinical benefit rate (CBR) was 17.9% (8.9%-30.4%). Pharmacokinetics (PK) were observed to be approximately dose-proportional across dose levels.


BG-C9074 showed a manageable safety and tolerability profile in patients with B7-H4 advanced solid tumors, including breast cancer. There were 5 dose-limiting toxicities (DLTs) reported among 3 dose levels, all related to treatment: grade 3 fatigue (n=1); grade 3 febrile neutropenia (n=2); and grade 4 platelet count decreased (n=2). The most common treatment-emergent adverse events (TEAEs) were nausea, fatigue, and neutropenia*. The most common grade ≥3 TEAEs were neutropenia and thrombocytopenia†. There were no TEAEs leading to treatment discontinuation or death.


These data support the continued development of BG-C9074 in patients with advanced solid tumors. (NCT06233942)


BG-68501, a CDK2 inhibitor (Abstract# 3115)


Dose-escalation data from the first-in-human, Phase 1a study of a novel CDK2 inhibitor, BG-68501, were presented as a poster today. BG-68501 is designed to address elevated CDK2 activity as well as cyclin E1-driven upregulation, two key resistance mechanisms that often limit the effectiveness of CDK4/6 inhibitors in treating HR+/HER2- breast cancer. CDK inhibitors target checkpoint proteins that control cell division to stop the growth of cancer cells.


A total of 57 enrolled patients with advanced solid tumors, including 19 patients with HR+/HER2- metastatic breast cancer, received BG-68501 as monotherapy or in combination with fulvestrant in escalating dose cohorts (all received prior CDK4/6i).


Of the 37 efficacy-evaluable patients (all with monotherapy), unconfirmed overall response rate (ORR) was 5.4% (2/37; 95% CI: 0.7%–18.2%). Two extensively pretreated patients (5.4%) experienced unconfirmed partial response (PR), 15 patients (40.5%) had stable disease (SD), 15 patients (40.5%) had progressive disease (PD), and 5 patients (13.5%) were not evaluable/not assessed. Of the 2 patients with PR, both were breast cancer patients, and one was ongoing with treatment at the time of data cutoff, while the other had discontinued treatment. Unconfirmed clinical benefit rate (CBR) was 8.1% (3/37; 95% CI: 1.7%-21.9%) and unconfirmed disease control rate (DCR) was 45.9% (17/37; 95% CI: 29.5%-63.1%). BG-68501 demonstrated a linear PK profile consistent with preclinical data and signs of pharmacodynamic responses.


BG-68501 demonstrated a manageable safety and tolerability profile, with no DLTs observed to date during dose escalation. The most common TEAEs were vomiting, nausea, and fatigue, and TEAEs leading to treatment discontinuation occurred in 4 patients (7%) across all dose levels. There were no TEAEs leading to death.


The data support continued development of BG-68501 as a next-line option for tumors with CDK2 dependency. (NCT06257264)


For additional information about our presence at the 2025 ASCO Annual Meeting, please visit our meeting hub: congress.beonemedicines.com.


BeOne will host an investor R&D Day on June 26 at 8:30 am ET covering its deep and broad global innovation pipeline and platforms, as well as the Company's vision, differentiated capabilities, and value creation drivers. A live webcast will be accessible from the investors section of BeOne’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, or https://sseir.beonemedicines.com. An archived replay will be available for 90 days following the event.


About Our Breast Cancer Pipeline


BeOne is advancing a robust portfolio of investigational medicines for breast cancer, including three molecules in clinical development – two cyclin-dependent kinase (CDK) inhibitors, BGB-43395, a CDK4 inhibitor, and BG-68501, a CDK2 inhibitor, and an antibody-drug conjugate (ADC), BG-C9074. BeOne also plans to evaluate the potential of BCL2 inhibition in breast cancer, with next-generation BCL2 inhibitor, BGB-21447, expected to begin clinical testing in solid tumor indications soon. Multispecific antibodies and targeted protein degraders with potential applications in breast cancer are among the preclinical assets being developed.


About Breast Cancer


Breast cancer accounts for close to one in four cancer cases and one in six cancer deaths in women worldwide.1 Globally, breast cancer is the second most common cancer and the fourth highest cause of cancer mortality as well as the leading cause of cancer death in women.1 More than 2.3 million patients were diagnosed with breast cancer in 2022, and over 666,000 deaths were reported globally.1 Approximately two-thirds of breast cancer cases are the HR+/HER2- subtype.2


About BeOne


BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.


To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.


Forward-Looking Statement


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential of BeOne’s B7-H4-targeting ADC and CDK2 inhibitor to address critical gaps in breast cancer treatment; the ability of BeOne to deliver impactful therapies to cancer patients worldwide; the ability of BeOne’s pipeline to effectively combat breast cancer and improve quality of life for patients; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.


To access BeOne media resources, please visit our News & Media site.


*Neutropenia was defined by a custom MedDRA basket with neutropenia and neutrophil count decrease preferred terms.


†Thrombocytopenia was defined by a custom MedDRA basket with thrombocytopenia and platelet count decreased preferred terms.


1 Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. April 4, 2024. https://doi.org/10.3322/caac.21834


2 National Cancer Institute, SEER. Cancer Stat Facts: Female Breast Cancer Subtypes. https://seer.cancer.gov/statfacts/html/breast-subtypes.html Accessed November 11, 2024.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250602546858/en/



Permalink

https://www.aetoswire.com/en/news/02065202547125


Contacts

Investor Contact

Liza Heapes

+1 857-302-5663

ir@beonemed.com


Media Contact

Kim Bencker

+1 610-256-8932

media@beonemed.com

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

 SAN CARLOS, Calif. - Monday, 02. June 2025 AETOSWire Print 


BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational status


At 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data


 


(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.


Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in line with recent fixed-duration studies in fitter, healthier patient populations. Additionally, 11 patients in Arm D were able to discontinue treatment early due to meeting uMRD-guided stopping criteria, and 9 patients remain in ongoing clinical remission with sustained uMRD (1 patient discontinued study while in clinical remission), allowing them to remain treatment-free. In patients without del(17p) and TP53 mutations, 43% achieved uMRD by cycle 16 and 60% by cycle 28. These data were published today in the Journal of Clinical Oncology.


“While many first-line CLL studies have excluded patient populations with high-risk disease features, BeOne included those patients in SEQUOIA,” said Lai Wang, Ph.D., Global Head of R&D at BeOne. “Nearly 88% of patients with del(17p) and /or TP53 treated with BRUKINSA plus venetoclax remain progression-free at 36 months, which represents an unprecedented outcome for a doublet regimen in this difficult-to-treat patient population. These new SEQUOIA data reinforce BRUKINSA’s versatility across the spectrum of CLL patients and reflect BeOne’s commitment to progressing a pipeline built to meet unmet patient needs and elevate the standard of care.”


Arm D Highlights (Abstract 7009)

SEQUOIA Arm D investigated BRUKINSA plus venetoclax in 114 patients with treatment-naïve (TN) CLL / small lymphocytic lymphoma (SLL) with or without del(17p) and/or TP53 high-risk mutations. At a median follow-up of 31.2 months, the combination induced a high 24-month progression-free survival (PFS) rate of 92% (95% CI, 85-96%) and an impressive overall response rate (ORR) of 97%. The 24-month overall survival (OS) rate was 96% (95% CI, 90%-98%). Of those patients with del(17p) and/or TP53 mutations, 94% were progression-free at 24 months and 87.6% were progression-free at 36 months.


The safety profile of BRUKINSA was consistent with the results of prior studies with no new safety signals identified.


“The zanubrutinib and venetoclax combination achieved deep, durable responses across risk groups, including patients with TP53 mutations, with a generally manageable safety profile. Notably, several patients were able to discontinue treatment and maintain remission, highlighting the potential for time-limited therapy with meaningful disease control,” said Mazyar Shadman, M.D., M.P.H., Associate Professor and Innovators Network Endowed Chair, Medical Director, Cellular Immunotherapy and the Bezos Family Immunotherapy Clinic at Fred Hutch Cancer Center. “Generating data to inform future CLL treatment strategies that allow for both continuous therapy and planned time off treatment is essential, particularly for high-risk patients who are the most likely to succumb to this disease.”


Arm C Highlights (Abstract 7011)

Arm C of the SEQUOIA study investigated BRUKINSA monotherapy in patients with TN CLL / SLL and del(17p) mutations and is the largest prospective cohort of CLL/SLL patients with del(17p). At a median follow-up of over 5.5 years (65.8 months), most patients remained progression-free. Notably, at 60 months, 72.2% of patients who received BRUKINSA remained progression-free (95% CI, 62.4, 79.8). When adjusted for the impact of the COVID-19 pandemic, 73.0% of patients in the cohort remained progression-free (95% CI, 63.3, 80.6) at 60 months. The 60-month OS rate was 85.1% (95% CI, 76.9, 90.6) and 87.0% (95% CI, 79.0, 92.1) when adjusted for COVID-19. At the time of data cut-off, the ORR was 97.3%, and 62.2% of patients were still receiving treatment with BRUKINSA.


The safety profile of BRUKINSA was consistent with the results of prior studies with no new safety signals identified.


For additional information about our presence at the 2025 ASCO Annual Meeting, please visit our meeting hub: congress.beonemedicines.com.


About Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a life-threatening cancer of adults. It is a type of mature B-cell malignancy in which abnormal leukemic B lymphocytes (a type of white blood cells) arise from the bone marrow and flood peripheral blood, bone marrow, and lymphoid tissues.1,2 CLL is the most common type of leukemia in adults, accounting for about one-third of new cases.2,3 Approximately 20,700 new cases of CLL will be diagnosed in the U.S. in 2024.3


About 50% of CLL patients have high-risk genetic features – including del(17p), TP53 or unmutated IGHV – that may limit the effectiveness of some treatments (e.g. chemotherapy) and increase the likelihood of disease progression.4,5


About SEQUOIA

SEQUOIA (NCT03336333) is a randomized, multicenter, global Phase 3 trial designed to evaluate the efficacy and safety of BRUKINSA in patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The trial consists of three cohorts:


Cohort 1 (n=479): randomized 1:1 to receive BRUKINSA (n=241) or bendamustine plus rituximab (n=238) until disease progression or unacceptable toxicity, in patients not harboring del(17p); data from this group comprise the primary endpoint;

Cohort 2/Arm C (n=110): patients with del(17p) receiving BRUKINSA as a monotherapy; and

Cohort 3/Arm D (n=114): 66 patients with del(17p) and/or pathogenic TP53 mutation and 47 patients without del(17p) or TP53 were enrolled, with 110 patients receiving BRUKINSA in combination with venetoclax.

The results of Cohort 1 of the SEQUOIA study led to the regulatory approval of BRUKINSA monotherapy in the treatment of TN CLL in many countries across the world, including approvals by the U.S. Food and Drug Administration and the European Medicines Agency. The primary endpoint of the trial is progression-free survival (PFS), as assessed by an independent review committee (IRC). Secondary endpoints include investigator-assessed PFS, IRC- and investigator-assessed overall response rate (ORR), overall survival (OS), and safety, as well as PFS and ORR in patients with del(17p).


About BRUKINSA® (zanubrutinib)

BRUKINSA is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.


BRUKINSA has the broadest label globally of any BTK inhibitor and is the only BTK inhibitor to provide the flexibility of once or twice daily dosing. Additionally, BRUKINSA is also the only BTK inhibitor to demonstrate superiority to another BTK inhibitor in a Phase 3 study.


The global BRUKINSA clinical development program includes about 7,100 patients enrolled in 30 countries and regions across more than 35 trials. BRUKINSA is approved in more than 75 markets, and more than 200,000 patients have been treated globally.


U.S. Indications and Important Safety Information for BRUKINSA (zanubrutinib)


INDICATIONS


BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with:


Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Waldenström’s macroglobulinemia (WM).

Mantle cell lymphoma (MCL) who have received at least one prior therapy.

Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.

Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy.

The MCL, MZL and FL indications are approved under accelerated approval based on overall response rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.


IMPORTANT SAFETY INFORMATION


Warnings and Precautions


Hemorrhage


Fatal and serious hemorrhage has occurred in patients with hematological malignancies treated with BRUKINSA. Grade 3 or higher hemorrhage including intracranial and gastrointestinal hemorrhage, hematuria, and hemothorax was reported in 3.8% of patients treated with BRUKINSA in clinical trials, with fatalities occurring in 0.2% of patients. Bleeding of any grade, excluding purpura and petechiae, occurred in 32% of patients.


Bleeding has occurred in patients with and without concomitant antiplatelet or anticoagulation therapy. Coadministration of BRUKINSA with antiplatelet or anticoagulant medications may further increase the risk of hemorrhage.


Monitor for signs and symptoms of bleeding. Discontinue BRUKINSA if intracranial hemorrhage of any grade occurs. Consider the benefit-risk of withholding BRUKINSA for 3-7 days before and after surgery depending upon the type of surgery and the risk of bleeding.


Infections


Fatal and serious infections (including bacterial, viral, or fungal infections) and opportunistic infections have occurred in patients with hematological malignancies treated with BRUKINSA. Grade 3 or higher infections occurred in 26% of patients, most commonly pneumonia (7.9%), with fatal infections occurring in 3.2% of patients. Infections due to hepatitis B virus (HBV) reactivation have occurred.


Consider prophylaxis for herpes simplex virus, pneumocystis jirovecii pneumonia, and other infections according to standard of care in patients who are at increased risk for infections. Monitor and evaluate patients for fever or other signs and symptoms of infection and treat appropriately.


Cytopenias


Grade 3 or 4 cytopenias, including neutropenia (21%), thrombocytopenia (8%) and anemia (8%) based on laboratory measurements, developed in patients treated with BRUKINSA. Grade 4 neutropenia occurred in 10% of patients, and Grade 4 thrombocytopenia occurred in 2.5% of patients.


Monitor complete blood counts regularly during treatment and interrupt treatment, reduce the dose, or discontinue treatment as warranted. Treat using growth factor or transfusions, as needed.


Second Primary Malignancies


Second primary malignancies, including non-skin carcinoma, have occurred in 14% of patients treated with BRUKINSA. The most frequent second primary malignancy was non-melanoma skin cancers (8%), followed by other solid tumors in 7% of the patients (including melanoma in 1% of patients) and hematologic malignancies (0.7%). Advise patients to use sun protection and monitor patients for the development of second primary malignancies.


Cardiac Arrhythmias


Serious cardiac arrhythmias have occurred in patients treated with BRUKINSA. Atrial fibrillation and atrial flutter were reported in 4.4% patients treated with BRUKINSA, including Grade 3 or higher cases in 1.9% of patients. Patients with cardiac risk factors, hypertension, and acute infections may be at increased risk. Grade 3 or higher ventricular arrhythmias were reported in 0.3% of patients.


Monitor for signs and symptoms of cardiac arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea, chest discomfort), manage appropriately, and consider the risks and benefits of continued BRUKINSA treatment.


Hepatotoxicity, Including Drug-Induced Liver Injury


Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI), has occurred in patients treated with Bruton tyrosine kinase inhibitors, including BRUKINSA.


Evaluate bilirubin and transaminases at baseline and throughout treatment with BRUKINSA. For patients who develop abnormal liver tests after BRUKINSA, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold BRUKINSA. Upon confirmation of DILI, discontinue BRUKINSA.


Embryo-Fetal Toxicity


Based on findings in animals, BRUKINSA can cause fetal harm when administered to a pregnant woman. Administration of zanubrutinib to pregnant rats during the period of organogenesis caused embryo-fetal toxicity, including malformations at exposures that were 5 times higher than those reported in patients at the recommended dose of 160 mg twice daily. Advise women to avoid becoming pregnant while taking BRUKINSA and for 1 week after the last dose. Advise men to avoid fathering a child during treatment and for 1 week after the last dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.


Adverse Reactions


The most common adverse reactions (≥30%), including laboratory abnormalities, in patients who received BRUKINSA (N=1729) are decreased neutrophil count (51%), decreased platelet count (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%).


Drug Interactions


CYP3A Inhibitors: When BRUKINSA is co-administered with a strong CYP3A inhibitor, reduce BRUKINSA dose to 80 mg once daily. For coadministration with a moderate CYP3A inhibitor, reduce BRUKINSA dose to 80 mg twice daily.


CYP3A Inducers: Avoid coadministration with strong or moderate CYP3A inducers. Dose adjustment may be recommended with moderate CYP3A inducers.


Specific Populations


Hepatic Impairment: The recommended dose of BRUKINSA for patients with severe hepatic impairment is 80 mg orally twice daily.


Please see full U.S. Prescribing Information including U.S. Patient Information.


About BeOne

BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne’s ability to deliver advanced and effective treatments for a broad range of cancer patients; BRUKINSA’s role across CLL patients; the ability of BeOne’s pipeline to meeting evolving patient needs and elevate the standard of care; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne’s ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.


To access BeOne media resources, please visit our News & Media site.


_______________________________


1 National Cancer Institute. Chronic Lymphocytic Leukemia Treatment (PDQ)–Patient Version. Accessed November 2024. https://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq.


2 American Cancer Society. What is Chronic Lymphocytic Leukemia? Updated May 10, 2018. Accessed November 2024. https://www.cancer.org/cancer/types/chronic-lymphocytic-leukemia/about/what-is-cll.html.


3 American Cancer Society. Key Statistics for Chronic Lymphocytic Leukemia. Updated July 1, 2024. Accessed November 2024. https://www.cancer.org/cancer/types/chronic-lymphocytic-leukemia/about/key-statistics.html.


4 Leukemia and Lymphoma Society. Chronic Lymphocytic Leukemia. Revised June 2021. Accessed November 5, 2024. https://www.lls.org/sites/default/files/2021-07/PS34_CLL_Booklet_2021.pdf.


5 Döhner H., Stilgenbauer S., James M.R., et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood. 1997;89(7):2516-2522.


 


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250531886517/en/



Permalink

https://www.aetoswire.com/en/news/2052025470944


Contacts

Investor Contact

Liza Heapes

+1 857-302-5663

ir@beonemed.com


Media Contact

Kim Bencker

+1 610-256-8932

media@beonemed.com